Accès ouvert
2025
conference-abstract
OpenAlex
Matteo Bimbati, Solène Fernandez, Stefano Sellitto, Sandesh Neupane et autres
Abstract Diffuse Midline Glioma (DMG) is a highly aggressive brainstem tumour, with a dismal median survival of less than one year despite extensive clinical trials. Over 80% of DMGs harbour histone-altering mutations, notably H3K27M, which results in global hypomethylation, dysregulate gene expression, …
ch, us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Vincenzo Mazza, Kamil Wojnicki, Antonela Petrović, Solène Fernandez et autres
Abstract Background Diffuse midline gliomas (DMGs) are aggressive paediatric brain tumours with a median survival of less than 12 months. PI3K/AKT pathway activation following treatment drives tumour progression by enhancing both glycolytic activity and oxidative phosphorylation (OXPHOS). The FOXO family (FOXO1/3/4/6), key …
ch, us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Ludovica Ciani, Antonela Petrović, Matteo Bimbati, Kamil Wojnicki et autres
Abstract Background Diffuse midline gliomas (DMGs) are amongst the most lethal pediatric brain tumors. Patients diagnosed with DMG face a dismal prognosis with an overall survival of 9-12 months from diagnosis. Somatic H3 K27M mutations drive global hypomethylation and maintains the stemness …
ch, us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Ludovica Ciani, Solène Fernandez, Micheal Grotzer, Sabine Müller et autres
Abstract BACKGROUND Diffuse midlines gliomas (DMGs) are lethal pediatric brain tumors, with an overall survival rate of less than 12 months. Radiotherapy treatment (RT) only provides a transient clinical response, with an average survival increase of about 3 months. At the cell …
ch, us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Ludovica Ciani, Sandra Laternser, Bettina Kritzer, Kerstin Hasler et autres
Abstract Diffuse Midline Gliomas (DMG) are amongst the most lethal pediatric brain tumors. Children diagnosed with DMG face a grim prognosis of 9-11 months from diagnosis. Over 85% of DMG patients harbor mutation affecting histone-encoding genes (H3.1K27M, H3.3K27M) leading to genome hypomethylation …
ch, es, us
(code pays fourni par la source)